SMMT logo

SMMT
Summit Therapeutics Inc

9,559
Mkt Cap
$11.99B
Volume
2.66M
52W High
$36.91
52W Low
$13.83
PE Ratio
-10.70
SMMT Fundamentals
Price
$16.12
Prev Close
$15.46
Open
$15.70
50D MA
$16.15
Beta
1.70
Avg. Volume
2.34M
EPS (Annual)
-$1.44
P/B
18.19
Rev/Employee
$0.00
$12,384.44
Loading...
Loading...
News
all
press releases
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% Higher - Time to Buy?
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6.5% - Still a Buy...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT
WINTON GROUP Ltd acquired a new stake in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired...
MarketBeat·2d ago
News Placeholder
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Zacks Research to Hold Rating
Zacks Research raised shares of Summit Therapeutics from a "strong sell" rating to a "hold" rating in a report on Thursday...
MarketBeat·7d ago
News Placeholder
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen ratings firms that are currently covering the company, Marketbeat...
MarketBeat·8d ago
News Placeholder
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT
Rafferty Asset Management LLC increased its position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 70.6% during the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·11d ago
News Placeholder
Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT
Vanguard Group Inc. boosted its stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 31.2% during the third quarter, according to the company in its most recent filing with the...
MarketBeat·12d ago
News Placeholder
Q1 EPS Estimate for Summit Therapeutics Increased by Analyst
Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) - Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Summit Therapeutics in a report released on Tuesday, February 24th. HC...
MarketBeat·15d ago
News Placeholder
Summit Therapeutics to Present at Upcoming Investor Conferences
Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit...
Business Wire·15d ago
News Placeholder
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
Zacks·16d ago
News Placeholder
Traders Purchase High Volume of Put Options on Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Investors bought 8,383 put options on the company. This represents an...
MarketBeat·18d ago
<
1
2
...
>

Latest SMMT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.